CN102482264B - 2-氨甲酰基-7-哌嗪基-苯并呋喃衍生物774 - Google Patents

2-氨甲酰基-7-哌嗪基-苯并呋喃衍生物774 Download PDF

Info

Publication number
CN102482264B
CN102482264B CN201080038560.6A CN201080038560A CN102482264B CN 102482264 B CN102482264 B CN 102482264B CN 201080038560 A CN201080038560 A CN 201080038560A CN 102482264 B CN102482264 B CN 102482264B
Authority
CN
China
Prior art keywords
ethyl
piperazin
pyridin
benzofuran
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080038560.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN102482264A (zh
Inventor
J.安德森
H.吉贝克
A.约翰森
C.E.林德
J.马尔姆斯特罗姆
G.诺德瓦尔
G.特普
T.维格尔特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akturam Life Co ltd
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN102482264A publication Critical patent/CN102482264A/zh
Application granted granted Critical
Publication of CN102482264B publication Critical patent/CN102482264B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201080038560.6A 2009-06-30 2010-06-29 2-氨甲酰基-7-哌嗪基-苯并呋喃衍生物774 Expired - Fee Related CN102482264B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22165709P 2009-06-30 2009-06-30
US61/221,657 2009-06-30
PCT/SE2010/050747 WO2011002405A1 (en) 2009-06-30 2010-06-29 2-carboxamide-7-piperazinyl-benzofuran derivatives 774

Publications (2)

Publication Number Publication Date
CN102482264A CN102482264A (zh) 2012-05-30
CN102482264B true CN102482264B (zh) 2015-10-07

Family

ID=43381415

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080038560.6A Expired - Fee Related CN102482264B (zh) 2009-06-30 2010-06-29 2-氨甲酰基-7-哌嗪基-苯并呋喃衍生物774

Country Status (14)

Country Link
US (2) US8367676B2 (enExample)
EP (1) EP2448934B1 (enExample)
JP (1) JP5767211B2 (enExample)
KR (1) KR20120110000A (enExample)
CN (1) CN102482264B (enExample)
AR (1) AR077301A1 (enExample)
AU (1) AU2010266753B2 (enExample)
BR (1) BRPI1014222A2 (enExample)
CA (1) CA2765475A1 (enExample)
MX (1) MX2011013449A (enExample)
RU (1) RU2011152516A (enExample)
TW (1) TW201103922A (enExample)
UY (1) UY32744A (enExample)
WO (1) WO2011002405A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8367676B2 (en) 2009-06-30 2013-02-05 Astrazeneca Ab 2-carboxamide-7-piperazinyl-benzofuran derivatives 774
CA2821480A1 (en) 2010-12-20 2012-06-28 Astrazeneca Ab 2-carboxamide-4-piperazinyl-benzofuran derivative
CN102993186B (zh) * 2012-12-20 2015-11-18 北京海步国际医药科技发展有限公司 一种新型的哌嗪衍生物
EP2964654A4 (en) * 2013-03-07 2016-08-10 Glaxosmithkline Llc THIEN [3,2-D] PYRIMIDIN-6-CARBOXAMIDE AND ANALOGUE AS SIRTUIN MODULATORS
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
WO2020160151A1 (en) * 2019-01-31 2020-08-06 Kyorin Pharmaceutical Co., Ltd. 15-pgdh inhibitors
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer
KR20230035036A (ko) * 2020-06-05 2023-03-10 모나쉬 유니버시티 이중 키나제-브로모도메인 억제제
EP4213832A4 (en) * 2020-09-18 2024-10-16 Merck Sharp & Dohme LLC Modified benzofuran-carboxamides as glucosylceramide synthase inhibitors
CN117430574B (zh) * 2023-12-20 2024-03-22 潍坊医学院 一种苯并呋喃衍生物及其制备方法、用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710149A (en) * 1991-12-05 1998-01-20 John Wyeth & Brother, Ltd. Piperazine derivatives as 5-ht antagonists
WO2003104227A1 (de) * 2002-01-20 2003-12-18 Bayer Healthcare Ag 2-heteroarylcarbonsäureamide
CN1805954A (zh) * 2003-06-16 2006-07-19 默克专利股份有限公司 用作血清素再摄取抑制剂的吲哚衍生物
CN1805953A (zh) * 2003-06-16 2006-07-19 默克专利股份有限公司 用作血清素再摄取抑制剂的吲哚衍生物
WO2008055808A1 (en) * 2006-11-09 2008-05-15 F. Hoffmann-La Roche Ag Indole and benzofuran 2-carboxamide derivatives

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK148392D0 (da) * 1992-12-09 1992-12-09 Lundbeck & Co As H Heterocykliske forbindelser
JP2003524571A (ja) * 1997-07-25 2003-08-19 ハー・ルンドベック・アクチエゼルスカベット インドール−及び２，３−ジヒドロインドール誘導体、その製造方法及びその使用方法
AR022303A1 (es) 1999-01-22 2002-09-04 Lundbeck & Co As H Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
MXPA03011638A (es) 2001-06-15 2004-04-02 Hoffmann La Roche Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6.
GB0227240D0 (en) 2002-11-21 2002-12-31 Glaxo Group Ltd Compounds
DE10259244A1 (de) * 2002-12-17 2004-07-01 Merck Patent Gmbh N-(Indolethyl-)cycloamin-Verbindungen
WO2005077885A1 (en) 2004-02-06 2005-08-25 Yale University Ruthenium-catalyzed hydroamination of olefins
WO2006062481A1 (en) 2004-12-09 2006-06-15 Biovitrum Ab New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders .
WO2007053093A1 (en) 2005-11-04 2007-05-10 Astrazeneca Ab Chroman compounds as 5 ht1b antagonists
AR059356A1 (es) 2006-02-14 2008-03-26 Astrazeneca Ab Nuevos radioligandos
US20100004452A1 (en) 2006-09-26 2010-01-07 Barbara Bertani 5-quinolinone derivatives as 5ht1a receptor modulators for treating sexual dysfunction, cognition impairment, psychotic disorders, anxiety, depression, etc.
US8367676B2 (en) 2009-06-30 2013-02-05 Astrazeneca Ab 2-carboxamide-7-piperazinyl-benzofuran derivatives 774

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710149A (en) * 1991-12-05 1998-01-20 John Wyeth & Brother, Ltd. Piperazine derivatives as 5-ht antagonists
WO2003104227A1 (de) * 2002-01-20 2003-12-18 Bayer Healthcare Ag 2-heteroarylcarbonsäureamide
CN1805954A (zh) * 2003-06-16 2006-07-19 默克专利股份有限公司 用作血清素再摄取抑制剂的吲哚衍生物
CN1805953A (zh) * 2003-06-16 2006-07-19 默克专利股份有限公司 用作血清素再摄取抑制剂的吲哚衍生物
WO2008055808A1 (en) * 2006-11-09 2008-05-15 F. Hoffmann-La Roche Ag Indole and benzofuran 2-carboxamide derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Timo Heinrich,等.Synthesis and Structure-Activity Relationship in a Class of Indolebutylpiperazines as Dual 5-HT1A Receptor Agonists and Serotonin Reuptake Inhibitors.《J. Med. Chem.》.2004,第47卷(第19期),第4684-4692页. *

Also Published As

Publication number Publication date
BRPI1014222A2 (pt) 2017-05-16
AR077301A1 (es) 2011-08-17
US8367676B2 (en) 2013-02-05
KR20120110000A (ko) 2012-10-09
CN102482264A (zh) 2012-05-30
EP2448934B1 (en) 2014-05-21
AU2010266753B2 (en) 2013-08-08
RU2011152516A (ru) 2013-08-10
WO2011002405A1 (en) 2011-01-06
AU2010266753A1 (en) 2012-01-19
EP2448934A4 (en) 2012-12-05
UY32744A (es) 2011-01-31
TW201103922A (en) 2011-02-01
US8859534B2 (en) 2014-10-14
JP2012532125A (ja) 2012-12-13
US20100331341A1 (en) 2010-12-30
EP2448934A1 (en) 2012-05-09
JP5767211B2 (ja) 2015-08-19
CA2765475A1 (en) 2011-01-06
US20130296296A1 (en) 2013-11-07
MX2011013449A (es) 2012-02-13

Similar Documents

Publication Publication Date Title
CN102482264A (zh) 2-氨甲酰基-7-哌嗪基-苯并呋喃衍生物774
EP1532113B1 (en) Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
JP5841651B2 (ja) ベンゾフラン誘導体
JP5749162B2 (ja) Ｃｂ２受容体を調節するスルホン化合物
JPWO2000071517A1 (ja) フェノキシプロピルアミン化合物
WO2007140005A2 (en) Oxazolyl piperidine modulators of fatty acid amide hydrolase
KR101386679B1 (ko) 신규한 아릴피페라진-함유 이미다졸 4-카복사마이드 유도체 및 이를 포함하는 약학 조성물
EP2167466A1 (en) N-phenyl hydrazides as modulators of the ghrelin receptor
CN103380129B (zh) 2-甲酰胺-4-哌嗪基-苯并呋喃衍生物
CN1177847C (zh) 作为5－ht2a拮抗剂的噁唑烷酮类化合物
CN1314674C (zh) 2－氨基－二氢噻唑衍生物及其作为诱导型no－合酶抑制剂的用途
JP6943239B2 (ja) Ｋｃｎｑ２〜５チャネル活性化剤
MX2007016541A (es) Compuestos quimicos.
WO2007079928A1 (de) Substituierte oxazol-derivate mit analgetischer wirkung
WO2011059207A2 (en) Arylpiperazine-containing purine derivatives and uses thereof
US6110943A (en) N-substituted (thiophen-2-yl)-piperidines and tetrahydropyridines as serotonergic agents
JP2023528547A (ja) 少なくとも１つのｎを含む５員ヘテロアリール誘導体、ならびにこれを有効成分として含有する精神障害の予防または治療に使用するための医薬組成物
CZ2000947A3 (cs) Substituované chromanové deriváty

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20190822

Address after: Solna, Sweden

Patentee after: Akturam Life Co.,Ltd.

Address before: Swedish Sodertalje

Patentee before: ASTRAZENECA AB

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20151007

CF01 Termination of patent right due to non-payment of annual fee